Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Cell Cycle (Georgetown, Tex.)|February 19, 2016
Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entryLeslie A Parsels, Daria M Tanska, Joshua D Parsels, et al.International Journal of Radiation Oncology, Biology, Physics|March 16, 2016
Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication StressKyle C Cuneo, Meredith A Morgan, Mary A Davis, et al.Neoplasia (New York, N.Y.)|July 13, 2012
Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibitionVenkatasubbaiah A Venkatesha, Leslie A Parsels, Joshua D Parsels, et al.Neoplasia (New York, N.Y.)|November 21, 2015
Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination RepairTasneem Kausar, Jason S Schreiber, David Karnak, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2013
Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repairDongping Wei, Leslie A Parsels, David Karnak, et al.Molecular Cancer Research : MCR|November 15, 2017
PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP InhibitorsLeslie A Parsels, David Karnak, Joshua D Parsels, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2014
Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancerDavid Karnak, Carl G Engelke, Leslie A Parsels, et al.Molecular Cancer Therapeutics|January 14, 2009
Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cellsLeslie A Parsels, Meredith A Morgan, Daria M Tanska, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2019
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic CancerKyle C Cuneo, Meredith A Morgan, Vaibhav Sahai, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2013
Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776Carl G Engelke, Leslie A Parsels, Yushen Qian, et al.Pageof 3